Рекомендации по диагностике и ведению больных с дефицитом α₁-антитрипсина Испанского общества пульмонологии и торакальной хирургии (SEPAR)

1. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-antitrypsin deficiency. Am. J. Respir. Clin. Care Med. 2003; 168: 818–900.

2. Laurell C.B., Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scand. J. Clin. Invest. 1963; 15: 132–140.

3. Brantly M. Alpha-1-antitrypsin: not just an antiprotease. Extending the half-life of a natural antiinflammatory molecule by conjugation with polyethylene glycol. Am. J. Respir. Cell. Mol. Biol. 2002; 27: 652–654.

4. Blanco I.E., de Serres F.J., Fernández-Bustillo E. et al. Alpha1-antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Medical. Hypotheses. 2005; 64:7 59–769.

5. Sveger T. Liver disease in á1-antitrypsin deficiency detected by screening of 200,000 infants. N. Engl. J. Med. 1976; 294: 1316–1321.

6. Stockley R.A. α1 -antitrypsin: more than just deficiency. Thorax 2004; 59: 363–364.

7. Miravitlles M., Vila S., Torrella M. et al. Influence of deficient alpha-1-antitrypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir. Med. 2002; 96: 186–192.

8. Cox D., Levison H. Emphysema of early onset associated with a complete deficiency of alpha-1-antitrypsin (null homozygotes). Am. Rev. Respir. Dis. 1988; 137: 371-375.

9. DeMeo D.L., Silverman E.K. a1 -antitrypsin deficiency 2: genetic aspects of á1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59: 259–264.

10. Blanco I., De Serres F.J., Fernández-Bustillo E. et al. Déficit de alfa-1-antitripsina en Espańa (variantes deficientes PiS y PiZ): prevalencia estimada y número de sujetos deficientes calculados para cada fenotipo. Med. Clin. (Barc.) 2004; 123: 761–765.

11. Blanco I., de Serres F.J., Fernández-Bustillo E. et al. Estimates of the prevalence of alpha-1-antitrypsin deficiency Pi*S and Pi*Z alleles and the numbers at risk in Europe countries. Eur. Respir. J. 2006 (in press).

12. Blanco I., Fernández E., Bustillo E.F. et al. Alpha-1-antitrypsin Pi phenotypes S and Z in Europe: an analysis of the published surveys. Clin. Genet. 2001; 60: 31–41.

13. Silverman E.K., Pierce J.A., Province M.A. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann. Intern. Med. 1989; 111: 982–991.

14. McElvaney N.G., Stoller J.K., Buist A.S. et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha-1-antitrypsin deficiency. Alpha-1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394–403.

15. Eden E., Mitchell D., Mehlman B. et al. Atopy, asthma, and emphysema in patients with severe alpha-1-antitrypysin deficiency. Am. J. Respir. Crit. Care Med. 1997; 156: 68–74.

16. Wu M.C., Eriksson S. Lung function, smoking and survival in severe alpha-1-antitrypsin deficiency, PiZZ. J Clin Epidemiol. 1988;41:1157–65.

17. Sveger T., Piitulainen E., Arborelius M. Lung function in adolescents with alpha-1-antitrypsin deficiency. Acta Paediatr. 1994; 83: 1170–1173.

18. Piitulainen E., Tornling G., Eriksson S. Effect of age and occupational exposure to airway irritants on lung function in nonsmoking individuals with alpha-1-antitrypsin deficiency (PiZZ). Thorax 1997; 52: 244–248.

19. Piitulainen E., Tornling G., Eriksson S. Environmental correlates of impaired lung function in non-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 1998; 53: 939–943.

20. Janus E.D., Phillips N.T., Carrell R.W. Smoking, lung function, and alpha-1-antitrypsin deficiency. Lancet 1985; 1: 152–154.

21. Seersholm N., Kok-Jensen A., Dirksen A. Decline in FEV1 among patients with severe hereditary alpha-1-antitrypsin deficiency type PiZ. Am. J. Respir. Crit. Care Med. 1995; 152: 1922–1925.

22. Piitulainen E., Eriksson S. Decline in FEV 1 related to smoking status in individuals with severe alpha-1-antitrypsin deficiency (PiZZ). Eur. Respir. J. 1999; 13: 247–251.

23. Brantly M.L., Paul L.D., Miller B.H. et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency in adults with pulmonary symptoms. Am. Rev. Respir. Dis. 1988; 138: 327–336.

24. Seersholm N., Kok-Jensen A. Clinical features and prognosis of life time non-smokers with severe alpha-1-antitrypsin deficiency. Thorax 1998; 53: 265–268.

25. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV 1 decline in individuals with severe deficiency of alpha-1-antitrypsin. Am. J. Respir. Crit. Care Med. 1998; 158: 49–59.

26. Buist A.S., Burrows B., Eriksson S. et al. The natural history of air-flow obstruction in PiZ emphysema. Report of a NHLBI workshop. Am. Rev. Respir. Dis. 1983; 127 (suppl.): 43–45.

27. Seersholm N., Dirksen A., Kok-Jensen A. Airways obstruction and two-year survival in patients with severe alpha-1-antitrypsin deficiency. Eur. Respir. J. 1994; 7: 1985–1987.

28. Novoradovsky A., Brantly M.L., Waclawiw M.A. et al. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha-1-antitrypsin deficiency. Am. J. Respir. Cell. Mol. Biol. 1999; 20: 441–447.

29. Rodrguez F., de la Roza C., Jardi R. et al. Glutathione S-transferase P1 and lung function in patients with alpha-1-antitrypsin deficiency and COPD. Chest 2005; 127: 1537–1543.

30. Dawkins P.A., Dowson L.J., Guest P.J., Stockley R.A. Predictors of mortality in alpha-1-antitrypsin deficiency. Thorax 2003; 58: 1020–1026.

31. Seersholm N. Body mass index and mortality in patients with severe alpha-1-antitrypsin deficiency. Respir. Med. 1997; 91: 77–82.

32. Miravitlles M., Vidal R., Barros-Tizón J.C. et al. Estado actual del tratamiento sustitutivo en el enfisema congénito por déficit de alfa-1-antitripsina. Informe del Registro Nacional. Arch. Bronconeumol. 1999; 35: 446–454.

33. Blanco I, Fernández E. Alpha-1-antitrypsin Pi phenotypes S and Z in Spain: an analysis of the published surveys. Respir. Med. 2001; 95: 109–114.

34. Needham M., Stockley R.A. Alfa-1-antitrypsin deficiency: Clinical manifestations and natural history. Thorax 2004; 59: 441–445.

35. Dahl M., Tybjaerg-Hansen A., Lange P. et al. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha-1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann. Intern. Med. 2002; 136: 270–279.

36. Sandford A.J., Chagani T., Weir T.D. et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am. J. Respir. Crit. Care Med. 2001; 163: 469–473.

37. Sandford A.J., Weir T.D., Pare P.D. Genetic risk factors for chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 1380–1391.

38. Dahl M., Hersh C.P., Ly N.P. et al. The protease inhibitor PiS allele and COPD: a meta-analysis. Eur. Respir. J. 2005; 26: 67–76.

39. Turino G.M., Barker A.F., Brantly M.L. et al. Clinical features of individuals with PiSZ phenotype of alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 1996; 154: 1718–1725.

40. Álvarez-Granda L., Cabero-Pérez M.J., Bustamante-Ruiz A. et al. PiSZ phenotype in chronic obstructive pulmonary disease. Thorax 1997; 52: 659–661.

41. Miravitlles M., Vidal R., Torrella M. et al. Evaluación del tratamiento sustitutivo del enfisema por déficit de alfa-1antitripsina. Arch. Bronconeumol. 1994; 30: 479–484.

42. Stoller J.K. Clinical features and natural history of severe alpha-1-an-titrypsin deficiency. Roger S. Mitchell Lecture. Chest 1997; 111 (suppl. 6): 123S–128S.

43. Miravitlles M. Enfisema por déficit de alfa-1-antripsina: żes realmente una enfermedad infrecuente? Med. Clin. (Barc.) 2004; 123: 778–779.

44. Dawson L.J., Guest P.J., Stockley R.A. The relationship of chronic sputum expectoration to physiologic, radiologic and health status characteristics in alpha-1 antitrypsin deficiency (PiZ). Chest 2002; 122: 1247–1255.

45. Hill A.T., Campbell E.J., Bayley D.L. et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ). Am. J. Respir. Crit. Care Med. 1999; 160: 1968–1975.

46. Alpha-1-antitrypsin deficiency: memorandum from a WHO meeting. Bulletin of the WHO. 1997; 75: 397–415.

47. Miravitlles M., Vila S., Jardi R. et al. Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. Chest 2003;124: 404–406.

48. de la Roza C., Rodriguez-Frias F., Lara B. et al. Results of a case-detection programme for alpha-1-antitrypsin deficiency in COPD patients. Eur. Respir. J. 2005; 26: 616–622.

49. Seersholm N., Kok-Jensen A., Dirksen A. Survival of patients with severe alpha-1-antitrypsin deficiency with special reference to nonindex cases. Thorax 1994; 94: 695–698.

50. Vidal R., Miravitlles M., Jardi R. et al. Estudio de la frecuencia de los diferentes fenotipos de la alfa-1-antitripsina en una población de Barcelona. Med. Clin. (Barc.) 1996; 107: 211–214.

51. Jardi R., Rodriguez-Frias F., Casas F. et al. Molecular characterization of two variants of alpha-1-antitrypsin deficiency: Pi Mpalermo and Pi Plovel. Med. Clin. (Barc.) 1997; 109: 463–466.

52. Jardi R., Rodriguez-Frias F., López-Talavera J.C. et al. Characterization of the new alpha1antytrypsin deficient PiM type allele, PiM Vall d’Hebron (Pro369Ser). Hum. Hered. 2000; 50: 320–321.

53. Jardi R., Rodriguez F., Miravitlles M. et al. Identification and molecular characterization of the new alpha-1-antitrypsin deficient allele PI Y barcelona (Asp256—>Val and Pro391—>His). Hum. Mutat. 1998; 12: 213.

54. Rodriguez F., Jardi R., Costa X. et al. Rapid screening for alpha-1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am. J. Respir. Crit. Care Med. 2002; 166: 814–817.

55. Miravitlles M., Jardi R., Rodriguez-Frias F. et al. Utilidad de la cuantificación de la banda alfa-1 del proteinogramasérico en el cribado del déficit de alfa-1-antitripsina. Arch. Bronconeumol. 1998; 34: 536–540.

56. de la Roza C., Costa X., Vidal R. et al. Programa de cribado para el déficit de alfa-1-antitripsina en pacientes con EPOC mediante el uso de gota de sangre en papel secante. Arch. Bronconeumol. 2003; 39: 8–12.

57. Costa X., Jardi R., Rodriguez F. et al. Easy method for screening dried blood spot specimens on filter paper for alpha-1 antitrypsin deficiency. Eur. Respir. J. 2000; 15: 1111–1115.

58. Vidal R., Miravitlles M., y Grupo de Estudio del Déficit de Alfa-1-anti-tripsina. Informe del Registro Espańol de Pacientes con Déficit de Alfa-1-antitripsina. Arch. Bronconeumol. 1995: 31: 299–302.

59. Wencker M., for the International Registry on alpha-1-antitrypsin deficiency. New formation of the International Registry on alpha-1antitrypsin deficiency as a joint database of multiple national registries. Eur. Respir. J. 1998; 12 (suppl. 28): 382.

60. Luisetti M., Miravitlles M., Stockley R.A. Alpha-1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur. Respir. J. 2002; 20: 1050–1056.

61. Barberŕ J.A., Peces-Barba G., Agusti A.G.N. et al. Guia clinica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch. Bronconeumol. 2001; 37: 297–316.

62. Miravitlles M. Tratamiento de la enfermedad pulmonar obstructive crónica. Med. Clin. (Barc.) 2005; 125: 65–74.

63. Wewers M.D., Casolaro M.A., Sellers S.E. et al. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 1987; 316: 1055–1062.

64. Dirksen A., Dijkman J.H., Madsen F. et al. A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 1999; 160: 1468–1472.

65. Seersholm N., Wencker M., Banik N. et al. Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV 1 in patients with severe hereditary alpha-1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur. Respir. J. 1997; 10: 2260–2263.

66. Wencker M., Fuhrmann B., Banik N. et al. Longitudinal follow-up of patients with alpha-1-protease inhibitor deficiency before and during therapy with alpha-1-protease inhibitor. Chest 2001; 119: 737–744.

67. Miravitlles M., de Gracia J., Rodrigo M.J. et al. Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha-1-antitrypsin deficiency with and without bronchiectasis. Chest 1999; 116: 946–952.

68. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480–1485.

69. Stockley R.A., Bayley D.L., Unsal I., Dowson L.J. The effect of augmentation therapy on bronchial inflammation in alpha-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2002; 165: 1494–1498.

70. Hubbard R.C., Sellers S., Czerski D. et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha1-antitrypsin deficiency. J. A. M. A. 1988; 260: 1259–1264.

71. Stoller J.K., Fallat R., Schluchter M.D. et al. Augmentation therapy with alpha-1-antitrypsin: patterns of use and adverse events. Chest 2003; 123: 1425–1434.

72. Stoller J.K., Rouhani F., Brantly M. et al. Biochemical efficacy and safety of a new pooled human plasma alpha-1antitrypsin, Respitin. Chest 2002; 122: 66–74.

73. Miravitlles M., Vidal R., Barros-Tizón J.C. et al. Usefulness of a national Registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir. Med. 1998; 92: 1181–1187.

74. de la Roza C., Soy D., Lara B. et al. Can the intervals of exogenous alpha-1-antitrypsin (AAT) administration be lengthened? Am. J. Respir. Crit. Care Med. 2005; 2 (abstr. issue): A809.

75. Vidal R., Drobnic M.E., Sala F. et al. Farmacocinética de la alfa-1-antitripsina utilizada en el tratamiento sustitutivo del enfisema congénito grave. Arch. Bronconeumol. 2006 (in press).

76. Cassina P.C., Teschler H., Konietzko N. et al. Two-year results after lung volume reduction surgery in alpha-1-antitrypsin deficiency versus smoker’s emphysema. Eur. Respir. J. 1998; 12: 1028–1032.

77. Schwaiblmair M., Vogelmeier C., Fruhmann G. Long-term augmentation therapy in twenty patients with severe alpha1-antitrypsin deficiency–three-year follow-up. Respiration. 1997; 64: 10–15.

78. Schmidt E.W., Rasche B., Ulmer W.T. et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am. J. Med. 1988; 84 (suppl. 6A): 63–69.

79. Barker A.F., Siemsen F., Pasley D. et al. Replacement therapy for hereditary alpha-1-antitrypsin deficiency. A program for long-term administration. Chest 1994; 105: 1406–1410.

80. Gottlieb D.J., Luisetti M., Stone P.J. et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha-1-antitrypsin deficiency. The American-Italian AATD Study Group. Am. J. Respir. Crit. Care Med. 2000; 162: 2069–2072.

81. Stoller J.K., Aboussonan L.S. Alpha-1-antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708–712.